Not available
Quote | Oxford BioMedica (OTCMKTS:OXBDF)
Last: | $4.445 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $4.445 |
High: | $0 |
Low: | $0 |
Volume: | 26 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Oxford BioMedica (OTCMKTS:OXBDF)
2024-07-17 07:38:43 ET More on Oxford Biomedica plc Historical earnings data for Oxford Biomedica plc Financial information for Oxford Biomedica plc Read the full article on Seeking Alpha For further details see: Oxford Biomedica appoints Lucinda (Lucy) C...
2024-04-30 15:22:58 ET More on Oxford Biomedica plc Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript Historical earnings data for Oxford Biomedica plc Financial information for Oxford Biomedica plc Read the full article on Seeking Alpha F...
Message Board Posts | Oxford BioMedica (OTCMKTS:OXBDF)
Subject | By | Source | When |
---|---|---|---|
John Dawson to retire from Oxford Biomedica | georgejjl | investorshub | 01/17/2022 9:30:24 AM |
AstraZeneca vaccine is 79% effective against symptomatic Covid-19, | georgejjl | investorshub | 03/23/2021 1:30:21 AM |
WHO expert group recommends use of AstraZeneca vaccine | georgejjl | investorshub | 02/11/2021 3:37:12 AM |
AstraZenecas (Oxford BioMedica's) vaccine is poised to become | georgejjl | investorshub | 02/05/2021 6:00:33 PM |
WHP completes viral vector manufacturing centre for Oxford Biomedica | georgejjl | investorshub | 12/31/2020 1:59:28 AM |
News, Short Squeeze, Breakout and More Instantly...
EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Oxford Biomedica (OXBDF) is expected to report for Q4 2023 Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q4 2024 Express (02Z0:MU) is expected to report $-8.99 for Q4 2024 Express Inc. - Ord...
Oxford Biomedica (OXBDF) is expected to report for Q4 2023
LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emer...